GB202114532D0 - Lentiviral Vectors - Google Patents

Lentiviral Vectors

Info

Publication number
GB202114532D0
GB202114532D0 GBGB2114532.1A GB202114532A GB202114532D0 GB 202114532 D0 GB202114532 D0 GB 202114532D0 GB 202114532 A GB202114532 A GB 202114532A GB 202114532 D0 GB202114532 D0 GB 202114532D0
Authority
GB
United Kingdom
Prior art keywords
lentiviral vectors
lentiviral
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2114532.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GBGB2114532.1A priority Critical patent/GB202114532D0/en
Publication of GB202114532D0 publication Critical patent/GB202114532D0/en
Priority to PCT/GB2022/052584 priority patent/WO2023062365A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing
GBGB2114532.1A 2021-10-12 2021-10-12 Lentiviral Vectors Ceased GB202114532D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2114532.1A GB202114532D0 (en) 2021-10-12 2021-10-12 Lentiviral Vectors
PCT/GB2022/052584 WO2023062365A2 (en) 2021-10-12 2022-10-12 Lentiviral vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2114532.1A GB202114532D0 (en) 2021-10-12 2021-10-12 Lentiviral Vectors

Publications (1)

Publication Number Publication Date
GB202114532D0 true GB202114532D0 (en) 2021-11-24

Family

ID=78595017

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2114532.1A Ceased GB202114532D0 (en) 2021-10-12 2021-10-12 Lentiviral Vectors

Country Status (2)

Country Link
GB (1) GB202114532D0 (en)
WO (1) WO2023062365A2 (en)

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998007859A2 (en) 1996-08-23 1998-02-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO1999041397A1 (en) 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
US5952199A (en) 1996-05-07 1999-09-14 Genentech, Inc. Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
WO2000052188A1 (en) 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
WO2001079518A2 (en) 2000-04-19 2001-10-25 Oxford Biomedica (Uk) Limited Codon optimisation for expression in retrovirus packaging cells
WO2003064665A2 (en) 2002-02-01 2003-08-07 Oxford Biomedica (Uk) Limited Viral vector
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US20050002907A1 (en) 2000-10-06 2005-01-06 Kyri Mitrophanous Vector system
WO2005056057A1 (en) 2003-12-04 2005-06-23 Childrens Hospital Los Angeles Research Institute Minimal lentiviral vector system
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO2006010834A1 (en) 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Non-integrative and non-replicative lentivirus, preparation and uses thereof
WO2007071994A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Viral vectors
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
CA2408786C (en) 2000-05-12 2012-05-29 University Of Southern California Retroviral vectors comprising an enhanced 3' transcription termination structure
WO2015092440A1 (en) 2013-12-20 2015-06-25 Oxford Biomedica (Uk) Limited Viral vector production system
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
US20190276844A1 (en) 2009-12-04 2019-09-12 Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2021014157A1 (en) 2019-07-23 2021-01-28 Oxford Biomedica (Uk) Limited Enhancing production of lentiviral vectors
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519034A (en) * 1999-12-14 2005-02-25 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
DE102009021592A1 (en) * 2009-05-15 2010-11-18 Medizinische Hochschule Hannover ASLV vector system

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
US5952199A (en) 1996-05-07 1999-09-14 Genentech, Inc. Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998007859A2 (en) 1996-08-23 1998-02-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US7056699B2 (en) 1996-10-29 2006-06-06 Oxford Biomedia (Uk) Limited Lentiviral LTR-deleted vector
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US6287814B1 (en) 1997-09-18 2001-09-11 Salk Institute RNA export element and methods of use
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO1999041397A1 (en) 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO2000052188A1 (en) 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
WO2001079518A2 (en) 2000-04-19 2001-10-25 Oxford Biomedica (Uk) Limited Codon optimisation for expression in retrovirus packaging cells
CA2408786C (en) 2000-05-12 2012-05-29 University Of Southern California Retroviral vectors comprising an enhanced 3' transcription termination structure
US20050002907A1 (en) 2000-10-06 2005-01-06 Kyri Mitrophanous Vector system
WO2003064665A2 (en) 2002-02-01 2003-08-07 Oxford Biomedica (Uk) Limited Viral vector
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
WO2005056057A1 (en) 2003-12-04 2005-06-23 Childrens Hospital Los Angeles Research Institute Minimal lentiviral vector system
WO2006010834A1 (en) 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Non-integrative and non-replicative lentivirus, preparation and uses thereof
WO2007071994A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Viral vectors
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US20190276844A1 (en) 2009-12-04 2019-09-12 Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2015092440A1 (en) 2013-12-20 2015-06-25 Oxford Biomedica (Uk) Limited Viral vector production system
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
WO2021014157A1 (en) 2019-07-23 2021-01-28 Oxford Biomedica (Uk) Limited Enhancing production of lentiviral vectors
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Non-Patent Citations (85)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. M76180
"Oligonucleotide Synthesis: A Practical Approach", 1984, IRL PRESS
"Tissue Culture", 1973, ACADEMIC PRESS
ABE ET AL., J VIROL, vol. 72, no. 8, 1998, pages 6356 - 6361
ADAM ET AL., J.VIROL., vol. 65, 1991, pages 4985
ANTONIOU, M.N.SKIPPER, K.A.ANAKOK, O., HUM. GENE THER., vol. 24, 2013, pages 363 - 374
ATSCHUL ET AL., J. MOL. BIOL., 1990, pages 403 - 410
AUSUBEL, F. M ET AL.: "Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS
B. ROEJ. CRABTREEA. KAHN: "DNA Isolation and Sequencing: Essential Techniques", 1996, JOHN WILEY & SONS
BABITZKE P, Y. J.CAMPANELLI D., JOURNAL OF BACTERIOLOGY, vol. 178, no. 17, 1996, pages 5159 - 5163
BALAGGAN, K.SALI, R.R., GENE THER., vol. 19, 2012, pages 145 - 153
BALSANO, C. ET AL., BIOCHEM. BIOPHYS RES. COMMUN., vol. 176, 1991, pages 985 - 92
BEAUDOING ET AL., GENOME RES., vol. 10, 2000, pages 1001 - 1010
BERKHAUT ET AL., J. MOL. BIOL., vol. 252, 1995, pages 59 - 69
BROWN ET AL., SCIENCE, vol. 368, 2020, pages 413 - 417
BURNS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8033 - 7
CAPASSO, C ET AL., VIRUSES, vol. 6, 2014, pages 832 - 855
CHEN ET AL., J. VIROL, vol. 67, 1993, pages 2142 - 2148
CHUNG J HWHITELY MFELSENFELD G, CELL, vol. 74, 1993, pages 505 - 514
D. M. J. LILLEYJ. E. DAHLBERG: "Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology", 1992, ACADEMIC PRESS
DANGHU, J. VIROL., vol. 75, 2001, pages 809 - 20
DAS ET AL., J. VIROL., vol. 81, 2007, pages 7742 - 8
DAS ET AL., JOURNAL OF VIROLOGY, vol. 73, 1999, pages 81 - 91
DEGLON ET AL., HUMAN GENE THERAPY, vol. 11, 2000, pages 179 - 90
DERSE AND NEWBOLD, VIROLOGY, vol. 194, no. 2, 1993, pages 530 - 536
DEVEREUX ET AL., NUCLEICACIDS RESEARCH, vol. 12, 1984, pages 387
DICKINS ET AL., NATURE GENETICS, vol. 37, 2005, pages 1281 - 1288
ELBASHIR ET AL., EMBO J, vol. 20, no. 23, 3 December 2001 (2001-12-03), pages 6877 - 88
EMI ET AL., JOURNAL OF VIROLOGY, vol. 65, 1991, pages 1202 - 1207
FARRELL CM1WEST AGFELSENFELD G., MOL CELL BIOL, vol. 22, no. 11, June 2002 (2002-06-01), pages 3820 - 31
FEMS MICROBIOL LETT, vol. 177, no. 1, 1999, pages 187 - 50
FIELDING ET AL., BLOOD, vol. 91, no. 5, 1998, pages 1802 - 1809
FLAJOLET, M ET AL., J. VIROL., vol. 72, 1998, pages 6175 - 80
FLAJOLET, M. ET AL., J. VIROL, vol. 72, 1998, pages 6175 - 6180
GHATTAS, I.R. ET AL., MOL. CELL. BIOL., vol. 11, 1991, pages 5848 - 5859
GILMARTIN ET AL., GENES DEV., vol. 9, 1995, pages 72 - 83
HUTVAGNER ET AL., SCIENCE, vol. 293, no. 5531, 12 June 2001 (2001-06-12), pages 834 - 8
IWAKUMA ET AL., VIROL, vol. 261, 1999, pages 120 - 32
J ELLIS ET AL., EMBO J, vol. 15, no. 3, 1 February 1996 (1996-02-01), pages 562 - 568
J. M. POLAKJAMES O'D. MCGEE: "Situ Hybridization: Principles and Practice", 1990, OXFORD UNIVERSITY PRESS
J. SAMBROOKE. F. FRITSCHT. MANIATIS: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
JANG ET AL., ENZYME, vol. 44, 1990, pages 292 - 309
KANG ET AL., J. VIROL., vol. 76, 2002, pages 9378 - 9388
KATZ, M.G. ET AL., HUM. GENE THER.,, vol. 24, 2013, pages 914 - 927
KAYE ET AL., J VIROL, vol. 69, no. 10, October 1995 (1995-10-01), pages 6588 - 92
KHARYTONCHYK ET AL., PROC. NATL. ACAD. SCI. USA., vol. 113, 2016, pages 13378 - 13383
KLASENS ET AL., NUCLEIC ACIDS RES, vol. 27, 1999, pages 446 - 54
KOLDEJANSON, BMC BIOTECHNOL, vol. 9, 2009, pages 86
KOO ET AL., VIROLOGY, vol. 186, 1992, pages 669 - 675
KOTTERMAN, M.A.SCHAFFER, D.V., NAT. REV. GENET., vol. 15, 2014, pages 445 - 451
KUMAR MBRADOW BPZIMMERBERG J, HUM GENE THER, vol. 14, no. 1, 2003, pages 67 - 77
LEWIS ET AL., EMBO J, vol. 11, no. 8, 1992, pages 3053 - 3058
LUND ET AL., J. BIOL. CHEM., vol. 259, 1984, pages 2013 - 2021
MACEJAK AND SARNOW, NATURE, vol. 353, no. 91, 1991
MARTARANO ET AL., J VIROL, vol. 68, no. 5, 1994, pages 3102 - 3111
MARTY ET AL., BIOCHIMIE, vol. 72, 1990, pages 885 - 7
MAUNDER ET AL., NAT COMMUN, vol. 8, 27 March 2017 (2017-03-27), pages 8
MAURY ET AL., VIROLOGY, vol. 200, no. 2, 1994, pages 632 - 642
MORGAN, R.A.KAKARLA, S., CANCER J., vol. 20, 2014, pages 145 - 150
MORIARITY ET AL., NUCLEIC ACIDS RES, vol. 41, no. 8, April 2013 (2013-04-01), pages e92
MOUNTFORDSMITH, TIG, vol. 11, 1985, pages 179 - 184
MOUNTFORDSMITH, TIG, vol. 11, no. 5, May 1995 (1995-05-01), pages 179 - 184
MUHLEBACH, M.D. ET AL., RETROVIRUSES: MOLECULAR BIOLOGY, GENOMICS AND PATHOGENESIS, vol. 13, 2010, pages 347 - 370
NAVIAUX ET AL., J. VIROL., vol. 70, 1996, pages 2581 - 5
NILSON ET AL., GENE THER, vol. 3, no. 4, 1996, pages 280 - 286
PAZARENTZOS, E.MAZARAKIS, N.D., ADV. EXP. MED BIOL., vol. 818, 2014, pages 255 - 280
PELLETIERSONENBERG, NATURE, vol. 334, 1988, pages 320 - 325
PROUDFOOT, GENES & DEV., vol. 25, 2011, pages 1770 - 1782
RALPH ET AL., NATURE MEDICINE, vol. 11, 2005, pages 429 - 433
SCHAMBACH ET AL., MOLECULAR THERAPY, vol. 15, 2007, pages 1167 - 1173
STARK ET AL., ANNU REV BIOCHEM, vol. 67, 1998, pages 227 - 64
STEWART HJFONG-WONG LSTRICKLAND ICHIPCHASE DKELLEHER MSTEVENSON LTHOREE VMCCARTHY JRALPH GSMITROPHANOUS KA, HUM GENE THER, vol. 22, no. 3, March 2011 (2011-03-01), pages 357 - 69
STEWART, H. J.M. A. LEROUX-CARLUCCIC. J. SIONK. A. MITROPHANOUSP. A. RADCLIFFE, GENE THER, vol. 16, no. 6, June 2009 (2009-06-01), pages 805 - 14
TAKAGAKIMANLEY, MOLECULAR AND CELLULAR BIOLOGY, vol. 17, 1997, pages 3907 - 3914
TOUZOT, F. ET AL., EXPERT OPIN. BIOL. THER., vol. 14, 2014, pages 789 - 798
VALSESIA-WITTMAN ET AL., J VIROL, vol. 70, 1996, pages 2056 - 64
VERMASOMIA, NATURE, vol. 389, no. 6648, 1997, pages 239 - 242
WEST, S., BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 40, 2012, pages a009431 - 849
YANG ET AL., RETROVIROLOGY, vol. 4, no. 4, 2007, pages 4
YANG, STRUCTURE, vol. 19, 2011, pages 368 - 377
YAO FSVENSJO TWINKLER TLU MERIKSSON CERIKSSON E: "Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells", HUM GENE THER, vol. 9, 1998, pages 1939 - 1950, XP002105115
YEE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9564 - 9568
YU, PNAS, vol. 83, 1986, pages 3194 - 98
ZHENG, Y.W. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 22593 - 8
ZUFFEREY, R. ET AL., J. VIROL., vol. 73, 1999, pages 2886 - 92

Also Published As

Publication number Publication date
WO2023062365A2 (en) 2023-04-20
WO2023062365A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
GB201800903D0 (en) Vectors
SG11202001367QA (en) Retroviral vectors
IL291632A (en) Lentiviral vector formulations
GB202016862D0 (en) Vector
SG11202102012SA (en) Improved lentiviral vector
GB202205606D0 (en) Lentiviral vector
IL310364A (en) Improved crispr-cas technologies
GB202114532D0 (en) Lentiviral Vectors
GB202114528D0 (en) Lentiviral vectors
GB202114529D0 (en) Lentiviral vectors
GB202019108D0 (en) Vector
GB202003710D0 (en) Lentiviral vectors
GB202003711D0 (en) Lentiviral vectors
GB202003709D0 (en) Lentiviral vectors
EP3970211C0 (en) Submarine
IL308705A (en) Lentiviral vector
GB201913974D0 (en) Vector
GB202214990D0 (en) Lentiviral vector
GB202214973D0 (en) Lentiviral vector
GB202205615D0 (en) Lentiviral vector
GB202205608D0 (en) Lentiviral vector
IL304808A (en) Retroviral vectors
GB202114530D0 (en) Retroviral vectors
GB202019084D0 (en) Retroviral vectors
GB202108176D0 (en) Vector

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)